News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Ashland’s pharmaceutical business is well known for acetylenics, cellulosics, and film coatings
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
There is a fast resurgence in the transplant activities post COVID
Subscribe To Our Newsletter & Stay Updated
